Attivare Therapeutics

Attivare is a preclinical, venture-backed, immunotherapy company that is developing novel vaccines to address major unmet needs in oncology and infectious diseases. The fundamental innovation of our tech platform is to provide a modular, off-the-shelf, in vivo solution to control activation of immune cells, in contrast to current ex vivo methods that require complex and costly manufacturing. Our tech is supported by more than 30 publications in peer reviewed journals. The broader market opportunity is large; currently the cancer immunotherapy market is estimated at approximately $47B in 2015 and infectious disease market at approximately $93B in 2020. Our initial scope is to focus on advancing our first product through IND-enabling studies for acute myeloid leukemia (AML), advancing a second product in oncology to preclinical efficacy studies, and partnering our ongoing projects in viral and bacterial diseases.